Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the initiation of a Phase 2 trial evaluating the efficacy and safety of LB-102 in patients wit ...

Core Insights - Neuphoria Therapeutics Inc. is nearing the topline data release from its AFFIRM-1 Phase 3 trial of BNC-210 for social anxiety disorder (SAD), expected in early Q4 2025, which is a significant milestone for the company [1][3][10] - The company has extended its cash runway through fiscal Q2 2027, with a cash position of $14.2 million as of June 30, 2025 [5][10] Clinical Program Highlights - BNC-210 is an oral, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, being developed for SAD and PTSD, and has received FDA Fast Track designation [8][9] - The drug has shown rapid-onset and meaningful anti-anxiety effects in previous clinical trials without sedation or cognitive impairment [8][11] Financial Results - For the fiscal year ended June 30, 2025, Neuphoria reported a net loss of $0.4 million, significantly reduced from a net loss of $15.5 million in the previous year [7][18] - Research and development expenses decreased to $9.0 million from $9.4 million year-over-year, while general and administrative expenses also saw a decline from $8.5 million to $7.8 million [6][7] - The company generated $15.6 million in license revenue for the fiscal year 2025, compared to no revenue in 2024 [17] Strategic Partnerships and Future Plans - Neuphoria is collaborating with Merck & Co., Inc. on two positive allosteric modulator candidates for Alzheimer's disease, with one currently in a Phase 2 trial [10][11] - The company plans to initiate the SYMPHONY Phase 2b/3 trial for PTSD in the first half of 2026 [10]

As filed with the Securities and Exchange Commission on December 18, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Registration No. 333- FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MIRA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Florida 2834 85-3354547 (I.R.S. Employer Identification No.) 855 N Wolfe Stre ...